Gastrointestinal Cancer | Specialty

The OncLive Gastrointestinal Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of gastrointestinal (GI) cancers, including hepatocellular carcinoma, gastric cancer, pancreatic cancer, colorectal cancer, cholangiocarcinoma, esophageal cancer, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in GI cancers.

Dr. Raghav on Treatment Options in Newly Diagnosed mCRC

March 25th 2020

Kanwal Raghav, MBBS, MD, discusses treatment options in newly diagnosed metastatic colorectal cancer.

Dr. Overman on Second-Line Therapy Options for Colorectal Cancer

March 23rd 2020

Michael J. Overman, MD, discusses second-line therapy options for patients with colorectal cancer.

Dr. Shah on the Role of Immunotherapy in Gastroesophageal Cancer

March 21st 2020

Manish A. Shah, MD, discusses the role of immunotherapy in gastroesophageal cancer.

Dr. Choti on the Benefits of Neoadjuvant Chemotherapy in Pancreatic Cancer

March 21st 2020

Michael A. Choti, MD, discusses the benefit of neoadjuvant chemotherapy in pancreatic cancer.

Dr. Marshall on Challenges in CRC Treatment

March 21st 2020

John L. Marshall, MD, discusses the challenges in the colorectal cancer field.

Dr. Mizrahi on the Goal of the COMMIT Trial in dMMR Metastatic CRC

March 20th 2020

Jonathan Mizrahi, MD, discusses the goal of the phase III COMMIT trial in mismatch repair deficient colorectal cancer.

Olaparib Takes Key Regulatory Step Toward Japanese Approval in Pancreatic Cancer

March 19th 2020

Olaparib has received an orphan drug designation in Japan for the maintenance treatment of germline BRCA-mutated curatively unresectable pancreatic cancer.

Dr. Le on Treatment Approaches for Oligometastatic Colorectal Cancer

March 19th 2020

Phat Le, MD, assistant professor, Department of General Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses treatment approaches for patients with oligometastatic colorectal cancer (CRC).

Nivolumab/Ipilimumab Approval in Advanced HCC Calls for Nuanced Look at Available Data

March 16th 2020

Ghassan K. Abou-Alfa, MD, provides perspective on the accelerated approval of nivolumab and ipilimumab in advanced hepatocellular carcinoma.

Dr. Katz on Eligibility Criteria for Up-front Surgery in Pancreatic Cancer

March 14th 2020

Matthew H.G. Katz, MD, FACS, discusses the eligibility criteria for up-front surgery in patients with pancreatic cancer.

Dr. Putcha on the Utility of Blood-Based Assays in CRC

March 14th 2020

Girish Putcha, MD, PhD, discusses the utility of blood-based assays in colorectal cancer.

Targeted Agents and Immunotherapy Revamp Treatment in HCC, While Biomarkers Remain Elusive

March 13th 2020

Richard S. Finn, MD, the burst of available treatment options, the ongoing hunt for actionable biomarkers, and the importance of multidisciplinary care in hepatocellular carcinoma.

Dr. Pant on Exciting Data With PARP Inhibitors in Pancreatic Cancer

March 13th 2020

Shubham Pant, MD, discusses exciting data with PARP inhibitors in pancreatic cancer.

Dr. Armaghany on Gene Sequencing in CRC

March 13th 2020

Tannaz Armaghany, MD, discusses up-front gene sequencing in patients with colorectal cancer.

Dr. Sapisochin on Determining Transplant Eligibility in HCC

March 13th 2020

Gonzalo Sapisochin, MD, discusses factors that help determine transplant eligibility in hepatocellular carcinoma.

Dr. Chao on the Utility of MSI as a Biomarker in Gastric/GEJ Cancer

March 12th 2020

Joseph Chao, MD, discusses the utility of microsatellite instability (MSI) status as a prognostic biomarker in gastric and gastroesophageal cancer.

Dr. Huey on Sequencing Sorafenib Among Novel Combos in HCC

March 12th 2020

Ryan W. Huey, MD, discusses potential sequencing options with sorafenib among novel combination strategies in hepatocellular carcinoma.

TAS-102 Plus Bevacizumab Is Potential New Option in Refractory mCRC

March 12th 2020

The addition of bevacizumab to TAS-102 (trifluridine/tipiracil; Lonsurf) reduced the risk of disease progression or death compared with TAS-102 alone in patients with chemorefractory metastatic colorectal cancer.

Dr. Kaseb on the Progression of HCC Research

March 12th 2020

Ahmed O. Kaseb, MD, discusses the progression of therapy options for patients with hepatocellular carcinoma.

Dr. Nelson on the Benefit of Primary Tumor Resection in mCRC

March 11th 2020

Douglas A. Nelson, MD, associate professor in the Department of General Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the benefit of primary tumor resection in patients with metastatic colorectal cancer (mCRC).